ALFA FinderBSE filing, NSE: EVONILE. Summary written from the filing by ALFA Finder's alert engine.
Evonile Pharma Ltd: key numbers
- Share price
- ₹1,520.65
- Market cap
- ₹4,928 Cr
- Revenue (annual)
- ₹354.3 Cr
- Net profit (annual)
- ₹93.18 Cr
- P/E (TTM)
- -1235.1×Sector 43.8×
- Promoter holding
- 70.68%+0.00% QoQ
- FII holding
- 1.21%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Evonile Pharma Ltd
All →Evonile Pharma Fund Raise of ₹900 Cr
Evonile Pharma's board approved a partly paid rights issue of up to Rs 900 Crore. A committee will set the issue price, record date and entitlement.
- Value
- ₹900.0 Cr
Evonile Pharma Capital Structure Change
Evonile Pharma's Rights Issue Committee fixed November 11, 2026 as record date for a partly paid rights issue of 1,02,87,832 shares at Rs.860 each. Issue size is Rs.8,847.54 Million, with issue opening November 19, 2026.
- Value
- ₹884.8 Cr
- Execution
- Issue opening 19 Nov 2026 to closing 3 Dec 2026; listing on or about 9 Dec 2026
Evonile Pharma Earnings Call Transcript: Key Takeaways
Q2 FY27 revenue ₹56.1 cr (-38% YoY) and PAT loss ₹77.5 cr, including ₹68 cr exceptional items. H1 revenue ₹159.9 cr (-10%). Transitioning to an independent branded pharma model; Minipress XL acquired.
Evonile Pharma Results Update
Evonile Pharma reported Q2 FY27 revenue of ₹56.1 crore and an EBITDA loss of ₹31.8 crore. H1 FY27 profit after tax was a loss of ₹45.3 crore.
Evonile Pharma Investor Presentation: Key Takeaways
Q2 FY27 revenue fell 38% YoY to ₹56.1 cr, with a ₹77.5 cr net loss including ₹68 cr exceptional items. Transition from single-customer model to independent distribution continues.
Evonile Pharma Q2 FY27 Results: Net Loss of ₹77.5 Cr
Evonile Pharma posted a ₹775.4 million quarterly loss for September 2026 versus profit a quarter earlier. Exceptional items of ₹682.6 million drove the half-year pre-tax loss.
- Key figure
- Net loss ₹77.5 Cr
Other annual general meeting announcements
All →Muthoot Microfin Annual General Meeting
Muthoot Microfin seeks shareholder approval via postal ballot for material related party transactions with holding company Muthoot Fincorp. E-voting runs November 14 to December 13, 2026.
- Execution
- Approval sought for one year; remote e-voting from November 14, 2026 to December 13, 2026
Transgene Biotek Annual General Meeting
Transgene Biotek closed its register of members from December 24 to 30, 2026 for its 36th AGM. The e-voting cut-off date is December 23, 2026.
Centuple Global Annual General Meeting
Centuple Global's scrutinizer reported postal ballot results approving statutory auditor appointment and a designation change for a director. Both resolutions passed with over 99.99% of valid votes.
- Execution
- 5 years (FY 2026-27 to FY 2030-31)
Vedanta Aluminium Metal Annual General Meeting
Vedanta Aluminium Metal issued a postal ballot notice seeking member approval for material related party transactions by the company and its subsidiary BALCO. E-voting runs November 15 to December 14, 2026.
Indowind Energy Annual General Meeting
Indowind Energy issued a Postal Ballot Notice seeking shareholder approval for Dr. S.R. Shriraam Shekher's appointment as Independent Director for five years. E-voting via CDSL runs from 18 November to 17 December 2026.
Raksan Transformers Annual General Meeting
Raksan Transformers has issued the notice for its 31st AGM on December 5, 2026. Agenda includes financial statement adoption, auditor appointment, and registered office shift to Haryana.